Administration Case Report With EXPAREL

This case report represents the individual experience of Dr Brian R. Binetti and is intended to demonstrate his methodology for using EXPAREL in a specific bariatric procedure.

Pacira Pharmaceuticals, Inc. recognizes that there are alternative methodologies for administering local anesthetics, as well as individual patient considerations when selecting the dose for a specific procedure.

EXPAREL is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks.

### CASE INFORMATION

<table>
<thead>
<tr>
<th>Physician Name</th>
<th>Brian R. Binetti, MD, FACS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Affiliation</td>
<td>Director of Metabolic and Bariatric Surgery, Health Quest Medical Practice, Northern Dutchess Hospital, Rhinebeck, NY</td>
</tr>
<tr>
<td>Surgical Case Performed</td>
<td>Laparoscopic sleeve gastrectomy</td>
</tr>
<tr>
<td>Inpatient or Outpatient Procedure</td>
<td>Inpatient</td>
</tr>
</tbody>
</table>

### PATIENT CHARACTERISTICS

<table>
<thead>
<tr>
<th>Gender</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>60 years</td>
</tr>
<tr>
<td>Patient History and Characteristics</td>
<td>Morbidly obese (BMI 46.9 kg/m²) Comorbidities include hypertension and obstructive sleep apnea requiring CPAP</td>
</tr>
<tr>
<td>Pathology</td>
<td>Morbid obesity</td>
</tr>
</tbody>
</table>

### PROCEDURAL DETAILS

<table>
<thead>
<tr>
<th>Incision Size</th>
<th>5 total port sites: 4 × 5 mm, 1 × 12 mm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preoperative Analgesics Used</td>
<td>IV acetaminophen 1000 mg IV ketorolac 15 mg</td>
</tr>
<tr>
<td>Intraoperative Analgesics Used</td>
<td>200 mL of expanded EXPAREL for TAP blocks (150 mL) and port site infiltrations (50 mL)</td>
</tr>
</tbody>
</table>

### Dose of EXPAREL and Total Volume Used

<table>
<thead>
<tr>
<th>EXPAREL (266 mg)</th>
<th>Bupivacaine HCl 0.5%</th>
<th>Normal Saline</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 mL</td>
<td>30 mL</td>
<td>150 mL</td>
<td>200 mL</td>
</tr>
</tbody>
</table>

BMI, body mass index; CPAP, continuous positive airway pressure; IV, intravenous; TAP, transversus abdominis plane.

The recommended dose of EXPAREL is based on the size of the surgical site, the volume required to cover the area, and individual patient factors that may impact the safety of an amide local anesthetic. The maximum dose of EXPAREL should not exceed 266 mg.

EXPAREL can be administered unexpanded (20 mL) or expanded to increase volume up to a total of 300 mL (final concentration of 0.89 mg/mL [ie, 1:14 dilution by volume]) with normal (0.9%) saline or lactated Ringer’s solution.

Bupivacaine HCl may be administered immediately before EXPAREL or admixed in the same syringe, as long as the ratio of the milligram dose of bupivacaine HCl to EXPAREL does not exceed 1:2. Admixing may impact the pharmacokinetic and/or physiochemical properties of EXPAREL, and this effect is concentration dependent. The toxic effects of these drugs are additive and their administration should be used with caution, including monitoring for neurological and cardiovascular effects related to local anesthetic systemic toxicity. Other than with bupivacaine, EXPAREL should not be admixed with other drugs prior to administration.

Please see Important Safety Information on the last page and refer to the accompanying full Prescribing Information for complete Dosage and Administration information before using EXPAREL.
In this procedure, prior to the gastric bypass, Dr Binetti determined that a total volume of 200 mL would be needed for the TAP blocks (150 mL) and port site (50 mL) infiltrations. He expanded 20 mL of EXPAREL® (bupivacaine liposome injectable suspension) with 150 mL of normal saline and then admixed 30 mL of 0.5% bupivacaine HCl. In larger patients, Dr Binetti ensures he has adequate volume by expanding with additional normal saline for a total volume of up to 300 mL. Dr Binetti added bupivacaine HCl to provide short-term local analgesia that overlapped with the long-term local analgesia provided by EXPAREL.

For this procedure, Dr Binetti identified and marked key landmarks (xiphoid process, subcostal margins, midaxillary line, iliac crests) to assist with the TAP blocks and port site placements. He then divided the injectate into syringes and, using 22-gauge spinal needles, infiltrated as follows:

- **Step #1: Port Site Infiltration at Left Subcostal Region**
  - Dr Binetti infiltrated 10 mL of expanded EXPAREL into the left subcostal region prior to making a 5-mm incision. A Veress needle was then inserted, and the abdominal cavity was inflated with carbon dioxide.
  - Once the pneumoperitoneum was created, a 5-mm port was inserted under direct visualization. A 5-mm scope was then inserted to ensure that the port site infiltrations, port site placements, and TAP blocks were performed under direct visualization.

- **Step #2: Port Site Infiltration at Left Paramedian Region**
  - Dr Binetti infiltrated 10 mL of expanded EXPAREL into the left paramedian region prior to making a 12-mm incision. Following incision, a 12-mm port was inserted.

- **Step #3: TAP Blocks**
  - Starting at the right TAP, Dr Binetti infiltrated 35 mL of expanded EXPAREL along the right subcostal margin and 40 mL of expanded EXPAREL along the right midaxillary line, ending at the right iliac crest, for a total of 75 mL. He injected 2 to 3 mL every 1 to 2 cm along the plane. He then repeated this technique when infiltrating into the left TAP for a total of 150 mL of expanded EXPAREL for the TAP blocks.

- **Step #4: Local Infiltration of Remaining Port Sites**
  - Finally, Dr Binetti infiltrated 30 mL of expanded EXPAREL into the remaining port sites, using 10 mL at each of the three 5-mm port sites.

Laparoscopic view of a smooth transversus abdominis muscle bulge indicates that the needle penetration is at the appropriate depth and the injectate is in the TAP. This should be done under direct visualization to ensure that the needle does not penetrate the peritoneum.

Please see Important Safety Information on the last page and refer to the accompanying full Prescribing Information for complete Dosage and Administration information before using EXPAREL.
PROPER TECHNIQUE IS CRUCIAL FOR ANALGESIC COVERAGE

Dr Binetti infiltrated EXPAREL® (bupivacaine liposome injectable suspension) into each port site with a moving needle technique. The needle was injected down to the preperitoneal space and slowly withdrawn to the dermis level. With a moving needle technique, the injections were spread in a fan-like pattern as the needle was both inserted and withdrawn to maximize the coverage area. The goal was to create a column of EXPAREL injectate from the preperitoneal space up to the dermis for maximal analgesic coverage.

Infiltration Notes (cont)

Watch infiltration with EXPAREL in a laparoscopic sleeve gastrectomy procedure at www.EXPAREL.com

Important Safety Information

EXPAREL is contraindicated in obstetrical paracervical block anesthesia.

Adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via infiltration were nausea, constipation, and vomiting; adverse reactions reported with an incidence greater than or equal to 10% following EXPAREL administration via interscalene brachial plexus nerve block were nausea, pyrexia, and constipation.

If EXPAREL and other non-bupivacaine local anesthetics, including lidocaine, are administered at the same site, there may be an immediate release of bupivacaine from EXPAREL. Therefore, EXPAREL may be administered to the same site 20 minutes after injecting lidocaine.

EXPAREL is not recommended to be used in the following patient population: patients <18 years old and/or pregnant patients.

Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.

Warnings and Precautions Specific to EXPAREL

Avoid additional use of local anesthetics within 96 hours following administration of EXPAREL.

EXPAREL is not recommended for the following types or routes of administration: epidural, intrathecal, regional nerve blocks other than interscalene brachial plexus nerve block, or intravascular or intra-articular use.

The potential sensory and/or motor loss with EXPAREL is temporary and varies in degree and duration depending on the site of injection and dosage administered and may last for up to 5 days, as seen in clinical trials.

Warnings and Precautions for Bupivacaine-Containing Products

Central Nervous System (CNS) Reactions: There have been reports of adverse neurologic reactions with the use of local anesthetics. These include persistent anesthesia and paresthesia. CNS reactions are characterized by excitation and/or depression.

Cardiovascular System Reactions: Toxic blood concentrations depress cardiac conductivity and excitability which may lead to dysrhythmias, sometimes leading to death.

Allergic Reactions: Allergic-type reactions (e.g., anaphylaxis and angioedema) are rare and may occur as a result of hypersensitivity to the local anesthetic or to other formulation ingredients.

Chondrolysis: There have been reports of chondrolysis (mostly in the shoulder joint) following intra-articular infusion of local anesthetics, which is an unapproved use.

Disclosure: Dr Binetti is a paid consultant for Pacira Pharmaceuticals, Inc.